التفاصيل البيبلوغرافية
| العنوان: |
Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity. |
| المؤلفون: |
Kishton, Rigel J1 (AUTHOR) rkishton@lyell.com, Vodnala, Suman K1 (AUTHOR), Vizcardo, Raul1 (AUTHOR), Restifo, Nicholas P1 (AUTHOR) nrestifo@lyell.com |
| المصدر: |
Current Opinion in Immunology. Feb2022, Vol. 74, p39-45. 7p. |
| مصطلحات موضوعية: |
*T cells, *ANTINEOPLASTIC agents, *TUMOR-infiltrating immune cells, *TUMOR antigens, *CELLULAR recognition |
| مستخلص: |
• Administration of expanded tumor infiltrating lymphocytes (TILs) can mediate high response rates in cancer patients. • Clinical correlates of response include the stemness characteristics of infused T cells and polyclonal recognition of tumor antigens. • Improving T cell stemness and enriching for tumor-specific T cell clonotypes in clinical T cell products may improve therapeutic efficacy. • Next-generation strategies utilizing gene editing and reprogramming technologies may yield highly effective polyclonal T cell products. The administration of T cells as cellular therapy against advanced cancers has brought clinical benefit to many patients and has progressed the field of cancer research. However, current cell therapy treatments are not curative in most patients, particularly in those with solid tumors, and it remains to be seen how broadly and efficaciously they may be applied going forward. Recent research has begun to elucidate key factors that regulate the efficacy of cell therapy in cancer patients, including T cell stemness and the ability to effectively target tumor antigens and overcome tumor heterogeneity. In this review, we discuss key properties of clinically effective anti-cancer T cell therapies along with strategies to improve T cell characteristics to augment clinical efficacy in solid tumors. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
